Arrhythmogenic Right Ventricular Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Left Ventricular Non-compaction, Restrictive Cardiomyopathy
Conditions
Brief summary
This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.
Detailed description
Identification of novel biomarkers is needed to improve the diagnosis and prognosis of cardiomyopathy. Also,the marked variation of genes which is still unclear, may influence clinical outcomes is determined in part by genetic heterogeneity of the systemic response to pathological process. Specific aim: 1. Proteomics, microRNA-seq and metabolomics will be to determine the correlation of echocardiographic parameters of systolic and diastolic functional entry with circulating molecules 2. Genomics will be to determine the association of clinical outcome
Interventions
None listed
Sponsors
Chinese Academy of Medical Sciences, Fuwai Hospital
Beijing Anzhen Hospital
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. Subjects who was diagnosed as cardiomyopathy by medical history, clinical symptoms, laboratory tests including ECG, echocardiography. 2. Subject understands study requirements aand agrees to sign an informed consent form prior to any study procedures.
Exclusion criteria
1. Endocrine disease known to cause heart muscle disease (including infants of diabetic mothers) 2. History of rheumatic fever 3. Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation, iron overload or heavy metal exposure) 4. HIV infection or born to an HIV positive mother 5. Kawasaki disease 6. Immunologic disease 7. Uremia, active or chronic 8. Abnormal ventricular size or function that can be attributed to intense 9.physical training or chronic anemia 10.Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the onset of arrhythmia (except a patient with chronic arrhythmia, subsequently ablated, whose cardiomyopathy persists after two months is not to be excluded) 11.Malignancy 12.Pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary hypertension) 13.Ischemic coronary vascular disease 14.Association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy. | Five year | The primary objective of this study is to determine whether variation in genetic background or molecules influences clinical outcomes in cardiomyopathy. Differentially expressed molecules are reported in multi-omics. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Age for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| gender for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| Height for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| Past medical history for each participant including disease history, surgical history, and family | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| Life style for each participant including smoking history and drinking, specify how many years | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| blood lipids(LDL,HDL,VLDL) | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| creatine | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| urea | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| blood glucose | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| D-dimer | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| hsCRP | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| Weight for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | — |
| Re-hospitalization | One year/Three year/Five year | Patients are hospitalized due to heart failure with decreasing left ventricular ejection fraction or worsen symptoms. The data is collected during follow-up visit at 1/3/5 years after discharge |
| Heart transplantation | One year/Three year/Five year | Patients are underwent heart transplantation due to pump failure of heart.The data is collected during follow-up visit at 1/3 years after discharge |
| Malignant arrythmia | One year/Three year/Five year | Ventricular flutter and fibrillation, atrioventricular block,atrial fibrillation or other cardiac arrhythmia leads to syncope or should be Implantable Cardioverter-Defibrillator (ICD) implantation. |
| Worsening heart failure | One year/Three year/Five year | Worsen heart failure is defined as decreased ejection fraction(left ventricular ejection fraction decreased over 10%), left ventricular ejection fraction \<45% and enlarged heart size measured by echocardiography and changing level of New York Heart Association (NYHA) Functional Classification.And patients who undergo left ventricular assist device (LVAD) will also be included.The data is collected during follow-up visit at 3/6/9/12/36/60 months after enrollment. |
| RNA/micro RNA/long-noncoding RNA-sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting | — |
| Proteomics on Liquid Chromatograph Mass Spectrometer/Mass Spectrometer of plasma sample | The data is collected from lab in an average of 6 month after the sample recruiting | — |
| Exon sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting | — |
| Result of echocardiography-Ejection Fraction | Three year | The whole results of echocardiography report will be recorded. The indicate can reflect cardiac contraction function and be used for discriminating heart failure or non-heart failure as a main factor. |
| Result of echocardiography-Left Ventricular End Diastolic Diameter | Three year | The whole results of echocardiography report will be recorded. The indicate can reflect the size of heart and be used for determination of heart enlargement. |
| Result of echocardiography-E/A Ratio | Three year | The whole results of echocardiography report will be recorded. The indicate can reflect diastolic function. |
| All-cause death | One year/Three year/Five year | The data is collected during follow-up visit at 1/3/5 years after discharge |
Countries
China
Contacts
Primary ContactJie Du, PhD
Backup ContactYulin Li, PhD
Outcome results
None listed